Rankings
▼
Calendar
ICCC FY 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$19M
+25.4% YoY
Gross Profit
$9M
45.0% margin
Operating Income
$257,385
1.3% margin
Net Income
-$78,292
-0.4% margin
EPS (Diluted)
$-0.01
Cash Flow
Operating Cash Flow
$954,170
Free Cash Flow
-$2M
Stock-Based Comp.
$144,313
Balance Sheet
Total Assets
$44M
Total Liabilities
$12M
Stockholders' Equity
$33M
Cash & Equivalents
$10M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$19M
$15M
+25.4%
Gross Profit
$9M
$7M
+26.1%
Operating Income
$257,385
-$1M
+118.7%
Net Income
-$78,292
-$1M
+92.3%
← Q4 2020
All Quarters
Q1 2021 →